Companies › GeoVax
1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| GEO-CM04S1 Synthetic MVA-based SARS-CoV-2 vaccine | – | Phase 2 | COVID-19 Infection | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04977024 | GEO-CM04S1 | Phase 2 | COVID-19 Infection | Oncology | Dec 2026 |
Cash of $3m on 2026-06-30; operating cash outflow about $15m a year; runway about 3 months at that burn, to Sep 2026; 0 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
No annotated target.
–
Hangzhou Converd Abscint NV/SA Beijing Gene Key Life Technology CNBG-Virogin Biotech (Shanghai) Stella Pharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.